Regenxbio is a biotechnology company that develops gene-therapy treatments based on its adeno-associated virus (AAV) vector platform. The organization employs roughly 309 people and has experienced a net increase in staff, with 24 new hires exceeding 11 recorded departures. Its workforce spans scientific research, clinical development, and essential corporate functions that support the advancement of its therapeutic pipeline. Current staffing figures highlight how Regenxbio balances specialized scientific roles with operational and business support to move programs toward commercialization.
Engineering is the largest single department with 85 employees, accounting for about 28 % of the workforce and reflecting the technical expertise required for vector design and process development. Healthcare roles—including clinical, medical, and regulatory functions—total 60 employees (19 %), while Operations follows with 47 employees (15 %), overseeing manufacturing and supply chain activities. Business Management houses 34 employees (11 %), and smaller yet critical groups such as Finance & Administration (14), Quality (13), Marketing & Product (11), Program & Project Management (11), and Information Technology (10) round out the staff mix. An additional 24 employees are classified under “Other,” illustrating the breadth of support functions needed to sustain biotech research and development.
Regenxbio’s talent footprint is concentrated around the U.S. Mid-Atlantic biotech corridor. The largest contingent (142 employees, 46 %) is listed under “Other,” representing remote or flexible workers across multiple regions. Within specific sites, Washington, DC hosts 62 employees and serves as a prominent hub for corporate and government affairs. The company’s home base of Rockville, MD accounts for 46 employees, complemented by nearby Maryland locations such as Gaithersburg (18), Germantown (14), Frederick (9), Bethesda (5), Laurel (5), and Baltimore (4). A smaller presence of 4 employees is noted in Austin, TX, indicating a modest expansion beyond the Mid-Atlantic region.